HELP Helus Pharma Inc.
Financings ·
Helus Pharma sold 10,309,280 shares at US$4.85 in an underwritten offering that closed on June 25, 2026. The proceeds are meant partly for a Phase 3 depression program whose data are not due until the fourth quarter.
The January 2, 2026 filing covers the company's common shares. It relies on the SEC rule for a voluntary withdrawal by the issuer.
| Line | FY ended Mar 31, 2025 | FY ended Mar 31, 2024 |
|---|---|---|
| Research and development | C$54.9 million | C$32.4 million |
| Net income (loss) | -C$113.1 million | -C$78.1 million |
| Cash from operations | -C$101.3 million | -C$68.9 million |
| Cash and equivalents | C$135.0 million | C$209.0 million |
Our latest story on this, dated Jan 2, 2026: "Cybin Inc. (now Helus Pharma) files Form 25 to leave NYSE American". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 16, 2026: "Helus Pharma (Cybin Inc.) closes US$50 million share offering at US$4.85". The story links the filing or release it is based on. Read the story.
Helus Pharma Inc. trades under the ticker HELP on NEO.
Helus Pharma Inc. is listed on NEO. Our directory also records these other listings: GETTEX:R7E0; LS:A42NG7; LSX:A42NG7; NASDAQ:HELP.
The SEC Central Index Key (CIK) for Helus Pharma Inc. is 1833141. Its filings are on SEC EDGAR.
Our directory records Helus Pharma Inc. under Canada.
Our directory classifies Helus Pharma Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Helus Pharma Inc. is CA4234921076.
aibio.space lists Helus Pharma Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as A1.
Our latest story on Helus Pharma, dated Jul 16, 2026: "Helus Pharma (Cybin Inc.) closes US$50 million share offering at US$4.85". Helus Pharma sold 10,309,280 shares at US$4.85 in an underwritten offering that closed on June 25, 2026. The proceeds are meant partly for a Phase 3 depression program whose data are not due until the fourth quarter. Source.
SEC records list Helus Pharma Inc.'s filer category as: <br>Emerging growth company.
SEC records list its business address as 100 KING STREET WEST, TORONTO.
Helus Pharma Inc.'s fiscal year ends on March 31, per SEC records.
Its most recent filing in our record is a 6-K filed 2026-10-21. All of its filings are on SEC EDGAR. Source.
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Filed to remove its shares from exchange listing. SEC Form 25. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio